Black Diamond Therapeutics (BDTX) Competitors $1.42 +0.02 (+1.43%) Closing price 04:00 PM EasternExtended Trading$1.41 -0.01 (-0.70%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX vs. RGNX, BNTC, ALLO, ORKA, TKNO, TRDA, MREO, HRTX, CYRX, and CMPSShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include REGENXBIO (RGNX), Benitec Biopharma (BNTC), Allogene Therapeutics (ALLO), Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), Entrada Therapeutics (TRDA), Mereo BioPharma Group (MREO), Heron Therapeutics (HRTX), Cryoport (CYRX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. REGENXBIO Benitec Biopharma Allogene Therapeutics Oruka Therapeutics Alpha Teknova Entrada Therapeutics Mereo BioPharma Group Heron Therapeutics Cryoport COMPASS Pathways Black Diamond Therapeutics (NASDAQ:BDTX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Is BDTX or RGNX more profitable? Black Diamond Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Black Diamond Therapeutics' return on equity of -68.08% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% REGENXBIO -283.19%-70.65%-41.68% Do analysts recommend BDTX or RGNX? Black Diamond Therapeutics currently has a consensus target price of $14.60, suggesting a potential upside of 928.17%. REGENXBIO has a consensus target price of $31.88, suggesting a potential upside of 386.64%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals and insiders believe in BDTX or RGNX? 95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer BDTX or RGNX? In the previous week, REGENXBIO had 4 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for REGENXBIO and 2 mentions for Black Diamond Therapeutics. REGENXBIO's average media sentiment score of 1.70 beat Black Diamond Therapeutics' score of 1.15 indicating that REGENXBIO is being referred to more favorably in the news media. Company Overall Sentiment Black Diamond Therapeutics Positive REGENXBIO Very Positive Which has higher valuation & earnings, BDTX or RGNX? Black Diamond Therapeutics has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.27-1.12REGENXBIO$83.33M3.94-$263.49M-$4.61-1.42 Which has more risk & volatility, BDTX or RGNX? Black Diamond Therapeutics has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Does the MarketBeat Community believe in BDTX or RGNX? REGENXBIO received 388 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Black Diamond Therapeutics an outperform vote while only 65.53% of users gave REGENXBIO an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5571.43% Underperform Votes2228.57% REGENXBIOOutperform Votes44365.53% Underperform Votes23334.47% SummaryBlack Diamond Therapeutics beats REGENXBIO on 10 of the 16 factors compared between the two stocks. Remove Ads Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.46M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-1.0731.0021.7317.81Price / SalesN/A441.15379.1994.60Price / CashN/A168.6838.1534.64Price / Book0.633.476.464.00Net Income-$82.44M-$72.06M$3.20B$247.23M7 Day Performance13.60%9.33%6.54%7.26%1 Month Performance-17.44%-16.97%-8.55%-6.26%1 Year Performance-72.80%-29.10%10.33%-0.18% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics2.9188 of 5 stars$1.42+1.4%$14.60+928.2%-73.3%$80.46MN/A-1.0790Short Interest ↑Gap DownRGNXREGENXBIO4.7385 of 5 stars$6.33+7.5%$31.88+403.6%-65.0%$317.24M$83.33M-1.26370Positive NewsBNTCBenitec Biopharma2.1793 of 5 stars$13.27+5.1%$24.71+86.2%+141.3%$311.20M$80,000.00-8.7920Short Interest ↑ALLOAllogene Therapeutics3.0975 of 5 stars$1.43-1.4%$9.29+549.6%-62.4%$310.69M$22,000.00-0.92310ORKAOruka Therapeutics2.9254 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/ANews CoveragePositive NewsTKNOAlpha Teknova1.7518 of 5 stars$5.67+1.4%$8.50+49.9%+135.3%$302.99M$37.75M-7.66240Positive NewsGap DownTRDAEntrada Therapeutics2.9666 of 5 stars$7.92+0.3%$25.67+224.1%-38.8%$297.75M$210.78M4.98110Positive NewsMREOMereo BioPharma Group2.1229 of 5 stars$1.90-2.6%$7.71+306.0%-30.1%$294.78M$1M-31.6740HRTXHeron Therapeutics3.4748 of 5 stars$1.93+1.0%$5.67+193.6%-33.7%$294.00M$144.29M-10.72300News CoveragePositive NewsCYRXCryoport2.681 of 5 stars$5.66-1.9%$11.83+109.1%-67.6%$282.49M$228.39M-1.671,020CMPSCOMPASS Pathways3.2458 of 5 stars$3.02+6.0%$20.20+568.9%-65.1%$279.87MN/A-1.37120 Remove Ads Related Companies and Tools Related Companies RGNX Competitors BNTC Competitors ALLO Competitors ORKA Competitors TKNO Competitors TRDA Competitors MREO Competitors HRTX Competitors CYRX Competitors CMPS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDTX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BDTX Stock Free BDTX Stock Alerts